证券代码：300685 证券简称：艾德生物 公告编号：2024-074 厦门艾德生物医药科技股份有限公司 关于回购股份进展的公告 一、回购股份的进展情况 截止 2024 年 10 月 31 日，公司通过回购专用证券账户以集中竞价交易方式 实施回购股份 4,666,240 股，占公司目前总股本的 1.17%，回购股份的最高成交 价为 21.91 元/股，最低成交价为 17.20 元/股，支付的总金额为 85,835,044.00 元 （不含交易费用）。本次回购符合公司既定的回购股份方案及相关法律法规的要 求。 二、其他说明 公司回购股份的时间、回购股份数量及集中竞价交易的委托时间段等均符合 《深圳证券交易所上市公司自律监管指引第 9 号—回购股份》等相关规定。 1、公司未在下列期间内回购股份： （1）自可能对公司证券及其衍生品种交易价格产生重大影响的重大事项发 生之日或者在决策过程中，至依法披露之日内； （2）中国证监会和深圳证券交易所规定的其他情形。 2、公司以集中竞价交易方式回购股份的符合下列要求： 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 厦门艾德生 ...

Investment Rating - The investment rating for the company is "Outperform the Market" [3][9]. Core Views - The company demonstrated strong resilience in growth, achieving a revenue of 848 million yuan in the first three quarters of 2024, representing a year-on-year increase of 19.84%. The net profit attributable to the parent company reached 227 million yuan, up 30.82% year-on-year [1][9]. - The gross profit margin improved to 84.7%, reflecting economies of scale, while the net profit margin increased to 26.8% [1][9]. - The company has successfully launched innovative diagnostic products, including a lung cancer PCR gene test approved in multiple regions, which is expected to enhance its business lines [1][9]. Financial Performance Summary - Revenue for 2024 is projected to be 1.275 billion yuan, with a year-on-year growth of 22.2% [2][11]. - The net profit for 2024 is estimated at 319 million yuan, reflecting a growth of 21.9% [2][11]. - The company’s earnings per share (EPS) is expected to increase from 0.66 yuan in 2023 to 0.80 yuan in 2024 [2][11]. Profitability Metrics - The EBIT margin is projected to improve from 26.3% in 2023 to 27.5% in 2024 [2][11]. - The return on equity (ROE) is expected to be 16.3% in 2024, up from 15.4% in 2023 [2][11]. - The price-to-earnings (PE) ratio is forecasted to decrease from 36.9 in 2023 to 30.3 in 2024 [2][11]. Market Position and Growth Potential - The company is positioned as a leader in the field of tumor precision diagnostics, with a comprehensive product system that spans targeted therapy to immunotherapy [1][9]. - The successful international expansion of its products is anticipated to accelerate growth in the mid to long term [1][9].

Investment Rating - The report maintains a "Buy" rating for the company [5]. Core Views - The company achieved significant revenue and profit growth in Q3 2024, with operating income reaching 305 million yuan, a year-on-year increase of 22.53%, and net profit attributable to shareholders of 83 million yuan, up 77.58% year-on-year [2][3]. - The substantial increase in net profit is attributed to revenue growth and effective cost control measures [2]. - The company has seen a steady increase in R&D investment, with R&D expenses reaching 164 million yuan in the first three quarters of 2024, a year-on-year increase of 9.03% [2]. - Multiple products received approval in Japan, expanding the application of companion diagnostic products [3]. Summary by Sections Financial Performance - In Q3 2024, the company reported operating income of 305 million yuan, a 22.53% increase year-on-year, and a net profit of 83 million yuan, reflecting a 77.58% increase year-on-year [2]. - The net profit growth, excluding stock incentive expenses, was 44.62% year-on-year [2]. - The company forecasts net profits of 315 million yuan, 379 million yuan, and 454 million yuan for 2024, 2025, and 2026, respectively [3]. R&D and Product Approvals - The company’s R&D expenses for the first three quarters of 2024 were 164 million yuan, a 9.03% increase year-on-year [2]. - Several products received NMPA approval, including the PCR-11 gene product for lung cancer and companion diagnostic kits for targeted therapies [2][3]. Market Position and Future Outlook - The company is positioned as a leader in the domestic tumor companion diagnostic industry, with continuous growth expected due to ongoing collaborations and innovations [3]. - The report projects a price-to-earnings ratio (PE) of 32, 27, and 22 for 2024, 2025, and 2026, respectively, indicating a favorable valuation [3].

证券代码：300685 证券简称：艾德生物 公告编号：2024-073 该产品实际销售情况取决于未来市场的推广效果，目前尚无法预测其对公 司未来业绩的影响，敬请广大投资者谨慎决策，注意防范投资风险。 厦门艾德生物医药科技股份有限公司（以下简称"公司"）于近日获得由 国家药品监督管理局颁发的《中华人民共和国医疗器械注册证》，具体情况如 下： | 产品名称 | 人类IDH1基因突变检测试剂盒（荧光PCR法） | | --- | --- | | 注册分类 | III类 | | 注册证编号 | 国械注准20243402089 | | 注册证有效期 | 2024年10月24日-2029年10月23日 | | 预期用途 | 本试剂盒用于体外定性检测急性髓系白血病（AML）患者骨 髓样本DNA中人类异柠檬酸脱氢酶1（IDH1）突变基因，检 | | | 测的突变位点为：394C>A、395G>A、394C>T、395G>T | | | 和394C>G，用于艾伏尼布片（Tibsovo片）的伴随诊断。 | 一、医疗器械注册证的具体情况 二、对公司的影响 该产品用于筛选IDH1基因突变的急性髓系白血病患者，是我国同类首创药 物艾伏 ...

Investment Rating - The report maintains a "Buy" rating for the company [4][9]. Core Views - The company has shown steady growth in Q3, with performance meeting expectations. Rapid growth in overseas markets and pharmaceutical business is noted, alongside successful progress in innovative products [2][4]. - The target price has been raised to 31.16 CNY, up from the previous forecast of 24.61 CNY, reflecting significant improvements in cost reduction and efficiency [4][9]. Financial Performance Summary - For the first three quarters of 2024, the company achieved revenue of 848 million CNY, representing a year-on-year increase of 19.84%. The net profit attributable to shareholders was 227 million CNY, up 30.82% [9]. - The gross margin for Q1-3 2024 was 84.74%, an increase of 1.14 percentage points. The net profit margin improved to 26.80%, up 2.25 percentage points [9]. - The company’s EPS forecasts for 2024, 2025, and 2026 have been adjusted to 0.82 CNY, 1.03 CNY, and 1.28 CNY respectively, up from previous estimates [9][10]. Innovation and Product Development - The company has made significant strides in innovation, with several products receiving regulatory approval. Notably, a gene testing kit for FGFR2 was approved in Japan, and a PCR11 gene product for lung cancer was approved domestically [9]. - The company has also entered the special review process for an HRD testing kit, which is expected to enhance its competitive edge in the oncology diagnostics market [9]. Market Position and Valuation - The company’s market capitalization is approximately 10.05 billion CNY, with a current share price of 25.22 CNY [5]. - The company’s price-to-earnings ratio is projected to be 38 times for 2024, indicating a strong valuation compared to peers [11].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company achieved revenue of RMB 848 million in the first three quarters of 2024, a year-on-year increase of 20% [1] - Net profit attributable to the parent company was RMB 227 million, up 31% year-on-year [1] - In Q3 2024, revenue reached RMB 305 million, a 23% increase year-on-year, with net profit attributable to the parent company surging 78% to RMB 83.41 million [1] - The company's gross margin in Q3 2024 was 84.0%, up 0.4 percentage points year-on-year, while the net profit margin increased by 8.5 percentage points to 27.4% [1] - The company has 27 self-developed tumor gene detection products approved in China, with several being the only approved products in the domestic market [1] - R&D expenses in the first three quarters of 2024 were RMB 164 million, a 9.03% increase year-on-year [1] Financial Performance - The company's revenue is expected to grow from RMB 1.244 billion in 2024E to RMB 1.836 billion in 2026E, with a compound annual growth rate of 20.89% [4] - Net profit attributable to the parent company is projected to increase from RMB 321 million in 2024E to RMB 486 million in 2026E, with a growth rate of 22.33% [4] - The company's ROE is expected to rise from 16.45% in 2024E to 18.35% in 2026E [4] - The P/E ratio is forecasted to decrease from 29.52 in 2024E to 19.50 in 2026E, indicating potential undervaluation [4] Product and Market Position - The company's products have gained recognition in international markets, with ROS1 and PCR-11 gene detection products approved in Japan and included in local medical insurance [1] - The company has established dual R&D centers in Xiamen and Shanghai, focusing on PCR, NGS, IHC, and FISH technology platforms [1] - The company's products have consistently demonstrated high accuracy and usage rates in both domestic and international quality evaluations [1] Analyst Consensus - The company has received 18 "Buy" ratings and 14 "Overweight" ratings in the past six months, indicating strong market confidence [6] - The average market rating score is 1.67, which falls within the "Overweight" range [6]

二、监事会会议审议情况 1、审议通过《2024年第三季度报告》 表决结果：3票赞成，0票反对，0票弃权，本议案获表决通过。 证券代码：300685 证券简称：艾德生物 公告编号：2024-071 厦门艾德生物医药科技股份有限公司 第四届监事会第二次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 厦门艾德生物医药科技股份有限公司（以下简称"公司"或"艾德生物"） 第四届监事会第二次会议于2024年10月21日在厦门市海沧区鼎山路39号公司 会议室以通讯和现场表决相结合的方式召开，会议应到监事3人，实到监事3人， 符合公司章程规定的法定人数。本次会议通知于2024年10月18日以电子邮件等 形式发出，会议的通知和召开符合《公司法》与《公司章程》的规定。本次会议 由公司监事会主席王弘宇先生主持。 经审核，监事会认为董事会编制和审核的公司2024年第三季度报告的程序 符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了 公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 2024年第三季度报告具体内容详 ...

证券代码：300685 证券简称：艾德生物 公告编号：2024-070 厦门艾德生物医药科技股份有限公司 第四届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 厦门艾德生物医药科技股份有限公司（以下简称"公司"或"艾德生物"） 第四届董事会第二次会议于2024年10月21日在厦门市海沧区鼎山路39号公司 会议室以通讯和现场表决相结合的方式召开，会议应到董事7人，实到董事7人， 符合公司章程规定的法定人数。公司监事和高级管理人员列席了本次会议。本次 会议通知于2024年10月18日以电子邮件等形式发出，会议的通知和召开符合 《公司法》与《公司章程》的规定。本次会议由公司董事长LI-MOU ZHENG先 生主持。 公司严格按照相关规定，并根据自身实际情况，完成了2024年第三季度报 告的编制及审议工作。公司董事、高级管理人员就该报告签署了书面确认意见。 本议案已经公司董事会审计委员会审议通过。 2024年第三季度报告具体内容详见中国证监会指定的创业板信息披露网站。 三、备查文件 公司第四届董事会第二次会议决议。 特 ...

Financial Performance - Revenue for Q3 2024 reached 304.95 million yuan, a 22.53% increase year-over-year[3] - Net profit attributable to shareholders in Q3 2024 was 83.41 million yuan, up 77.58% year-over-year[3] - Basic earnings per share for Q3 2024 were 0.21 yuan, a 75% increase year-over-year[3] - Weighted average return on equity for Q3 2024 was 4.92%, up 2.08 percentage points year-over-year[3] - Total operating revenue increased to 847,967,831.38 yuan, up 19.8% compared to the previous year's 707,591,539.73 yuan[15] - Net profit attributable to the parent company's owners increased to 1,174,863,865.61 yuan, up 16.6% from 1,007,161,728.46 yuan[14] - Net profit attributable to parent company shareholders increased to RMB 227.27 million, up 30.8% YoY from RMB 173.73 million[16] - Revenue from sales of goods and services reached RMB 810.77 million, up 14.1% YoY from RMB 710.55 million[18] - Basic earnings per share increased to RMB 0.57, up 29.5% YoY from RMB 0.44[16] - Total comprehensive income increased to RMB 227.33 million, up 31.1% YoY from RMB 173.43 million[16] Cash Flow and Investments - Operating cash flow for the first three quarters of 2024 was 240.28 million yuan, an 11.63% increase year-over-year[3] - Investment cash flow for the first three quarters of 2024 improved by 84.88% year-over-year, primarily due to reduced cash outflows for financial investments[6] - The company's net cash flow from financing activities in the first three quarters of 2024 decreased by 108.79% year-over-year, mainly due to increased share repurchases[6] - Operating cash flow increased to RMB 240.28 million, up 11.6% YoY from RMB 215.25 million[18] - Investment cash outflow decreased to RMB 440.12 million, down 33.0% YoY from RMB 657.38 million[18] - Cash and cash equivalents at the end of the period increased to RMB 252.96 million, up 29.5% YoY from RMB 195.34 million[19] - Cash paid for employee compensation increased to RMB 237.96 million, up 11.6% YoY from RMB 213.15 million[18] - Cash paid for taxes increased to RMB 68.51 million, up 67.7% YoY from RMB 40.84 million[18] Assets and Liabilities - Total assets as of Q3 2024 stood at 2.04 billion yuan, a 5.21% increase from the end of the previous year[3] - Total assets reached 2,035,595,020.59 yuan, a 5.2% increase from 1,934,881,553.02 yuan[13] - Monetary funds grew to 736,841,008.77 yuan, up 33.3% from 552,789,166.67 yuan[12] - Accounts receivable increased to 573,843,961.58 yuan, up 9.8% from 522,446,717.63 yuan[12] - Inventory rose to 37,320,993.03 yuan, a 29.7% increase from 28,782,648.84 yuan[12] - Total current assets reached 1,743,106,265.64 yuan, up 7.6% from 1,620,471,886.98 yuan[12] - Total liabilities decreased to 227,134,222.05 yuan, down 1.9% from 231,560,646.94 yuan[13] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 18,844[8] - Forward Investment (Hong Kong) Limited holds 22.01% of the shares, totaling 87,701,616 shares[8] - Hong Kong Securities Clearing Company Limited holds 8.01% of the shares, totaling 31,911,806 shares[8] - Xiamen Yixiang Investment Partnership holds 5.03% of the shares, totaling 20,026,900 shares[8] - Xiamen Keying Investment Partnership holds 4.98% of the shares, totaling 19,866,146 shares[8] - Lin Zuohua holds 1.69% of the shares, totaling 6,741,471 shares, including 4,670,703 shares through a margin trading account[9] - The total number of restricted shares at the end of the period is 4,897,930, with 62,000 shares released and 900 shares added during the period[10] - The company's restricted shares include 4,327,500 shares held by 386 core management and technical (business) personnel under the 2023 restricted stock incentive plan[10] - Share repurchases in the first three quarters of 2024 increased by 164.74% year-over-year, totaling 136.78 million yuan[6] Operating Costs and Expenses - Operating costs rose to 596,597,050.32 yuan, a 14.1% increase from 522,953,544.65 yuan in the previous year[15] - R&D expenses grew to 164,361,893.33 yuan, up 9.0% from 150,754,888.33 yuan in the previous year[15] Government Subsidies and Other Income - Government subsidies for the first three quarters of 2024 totaled 11.40 million yuan, a 43.38% decrease year-over-year[6] - Fair value change income increased to RMB 6.41 million, up 24.3% YoY from RMB 5.16 million[16]

证券代码：300685 证券简称：艾德生物 公告编号：2024-069 厦门艾德生物医药科技股份有限公司 关于公司产品进入创新医疗器械特别审查程序的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 厦门艾德生物医药科技股份有限公司（以下简称"公司"）自主研发的产 品于近日进入国家药品监督管理局医疗器械技术审评中心创新医疗器械特别审 查程序，现将相关情况公告如下： 三、风险提示 公司仍需按照有关要求开展注册申请工作，医疗器械产品从注册申请到获 批上市存在不确定性；且公司尚无法预测该产品若获得医疗器械注册证后对公 司未来业绩的影响。敬请广大投资者谨慎决策，注意防范投资风险。公司将严 格按照相关规定，及时履行信息披露义务。 一、产品的基本信息 二、产品情况及对公司的影响 HRD试剂盒是PARPi（靶向多聚ADP-核糖聚合酶抑制剂）新药治疗的伴 随诊断产品。PARPi新药是一类用于以BRCA基因为核心的多基因多位点变异 肿瘤的靶向药物，覆盖卵巢癌、前列腺癌、乳腺癌、胰腺癌等多癌种，使用前 需要检测HRD状态。公司HRD试剂盒是国内首款进入"创新医疗器械"程序 的H ...